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Abstract
Background: Recent studies in experimental animals show that insulin-like growth factor 1 (IGF1) plays a trophic
role during development and tissue injury and that microglia are important sources of IGF1. However,
little information is available regarding the expression, regulation, and function of IGF1 and related proteins
in human brain cells. In the current study, we examined the expression of IGF1 and IGF2 in human microglia
in vivo and in vitro.
Methods: Expression of IGF1 and IGF2 was examined by immunohistochemistry in post-mortem human brain
sections derived from HIV+ and HIV− brains. In primary cultures of human fetal microglia, IGF1 and IGF2 mRNA and
protein expression was examined by Q-PCR, ELISA, and Western blot analysis. Additionally, the role of IGF1 and IGF2
in neuroprotection was examined in primary human neuronal glial cultures.
Results: Immunohistochemistry of human brain tissues showed that nonparenchymal cells (vessels and meninges),
as well as parenchymal microglia and macrophages were positive for IGF1, in both HIV encephalitis and control
brains, while IGF2 was undetectable. Cultured microglia expressed IGF1 mRNA and produced pg/ml levels of IGF1
protein; this was significantly suppressed by proinflammatory mediators, such as lipopolysaccharide (LPS), poly(I:C),
and IFNγ. The Th2 cytokines IL-4 and IL-13 had no significant effect, but the cAMP analog (dibutyryl cAMP)
significantly increased IGF1 production. In contrast, microglial IGF2 mRNA and protein (determined by Western blot)
were upregulated by LPS. IGF1 receptor (IGF1R) immunoreactivity was predominantly expressed by neurons,
and both IGF1 and IGF2 significantly protected neurons from cytokine (IL-1/IFNγ) induced death.
Conclusions: Our study in human brain tissues and cells indicates that microglia are important sources of
neurotrophic growth factors IGF1 and IGF2, and that microglial activation phenotypes can influence the growth
factor expression. Importantly, our results suggest that chronic neuroinflammation and upregulation of
proinflammatory cytokines could lead to neurodegeneration by suppressing the production of microglia-derived
neuronal growth factors, such as IGF1.
Keywords: Brain, Cytokines, Growth factors, HIV, Human, IGF1, IGF2, Inflammation, LPS, Microglia
* Correspondence: hyeon-sook.suh@einstein.yu.edu; sunhee.lee@einstein.yu.edu




© 2013 Suh et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited.
Suh et al. Journal of Neuroinflammation 2013, 10:37
http://www.jneuroinflammation.com/content/10/1/37
Background
Recent advances in microglial biology have revealed that
microglia may have important homeostatic functions [1].
Microglia in normal brain are very active in surveillance
of the normal neuronal environment and are the first cells
to respond to any subtle changes [2]. Furthermore, not all
activated microglia are toxic: microglia can contribute to
neural repair and regeneration through phagocytosis and
the production of anti-inflammatory and immunoregula-
tory mediators, as well as neuronal growth factors [3-6].
Recent studies in mice also indicate that microglia are dis-
tinct from monocytes in their origin, and that the two
myeloid populations may have somewhat separate anti-
genic and functional profiles [7,8]. These findings together
indicate that elucidating the microglial activation pheno-
types and their regulatory mechanisms is important in un-
derstanding of the pathogenesis of diseases of the central
nervous system (CNS).
In mice, the macrophage and microglial activation phe-
notypes are defined by the arginine metabolism pathway,
with the classically activated phenotype (M1) character-
ized by the expression of inducible nitric oxide synthase
(iNOS) and the alternatively activated phenotype (M2) by
the expression of arginase-1 [9,10]. Macrophage M1 and
M2 activation can typically be induced by exposure to
Th1 (IFNγ) and Th2 (IL-4 or IL-13) cytokines, respec-
tively. The primary role of M2 macrophages is in wound
healing and tissue repair, with arginase-1 contributing to
cell proliferation, resolution of inflammation, and remod-
eling of the extracellular matrix [9]. Considerably less in-
formation is available on the role of M2 microglia, but
there is evidence that microglia produce neuronal growth
factors IGF1, IGF2, and brain-derived growth factor
(BDNF) [6,11-13]. To what extent the M1/M2 paradigm
applies to human macrophages and microglia is uncertain,
since neither iNOS nor arginase 1 is expressed in these
cells [14,15].
IGF1 has emerged as a crucial factor in the CNS; it is
involved in normal cognitive function and successful
aging, in addition to development [16-19]. IGF1 belongs
to the insulin-like growth factor (IGF) family of proteins,
to which the agonists IGF1 and IGF2, the receptors IGF1R
and IGF2R, and several IGF-binding proteins (IGFBP1-7)
belong [20-22]. Both IGF1 and IGF2 signal through the
IGF1R leading to the growth and metabolic effects via the
downstream PI3K/Akt pathway. IGF2R is not a signaling
receptor but is instead involved in the capture and degra-
dation of extracellular IGF2 (and IGF1) during develop-
ment [23]. Although circulating blood IGF1 and IGF2
levels exert trophic effects on neurogenesis and neuronal
survival [18,20,24], CNS-derived or intrathecally derived
IGF1 is also important in maintaining normal brain func-
tion [25]. It has been shown that local and systemic levels
of IGF1 are altered in such CNS diseases as Alzheimer’s
disease [26]. IGF1, IGF2, IGFBP2, and IGFBP3 levels
are also altered in individuals with HIV infection [27,28].
We have also recently reported that IGF2R is highly
upregulated in HIV-infected CNS and that IGF2R is a
novel IFNγ-inducible microglial protein that functions as
a positive regulator of HIV infection [29]. Given these pro-
vocative findings and the significant species-dependent
differences in neuroinflammatory mechanisms, we exam-
ined the regulation of IGF1 and IGF2 expression in hu-
man microglia in vivo and in vitro.
Methods
Human brain sections and IGF1 and IGF2
immunohistochemistry
Post-mortem brain sections with neuropathologic diag-
nosis of HIV encephalitis (HIVE) or minimal nonspecific
changes (normal-appearing brains from both HIV+ and
HIV− individuals) were obtained from the Manhattan
HIV Brain Bank and processed for immunohistochemis-
try as previously described [29-31]. Briefly, sections were
deparaffinized and underwent antigen retrieval in a citrate
buffer at 95°C for 20 min. The primary antibody used
was a rabbit polyclonal antibody (prediluted) against full-
length recombinant human IGF1 (Abcam, catalog no.
ab15320) based on its reaction on control sections. Posi-
tive controls for IGF1 included paraffin-embedded human
fetal brain (strong staining of meninges and meningeal
macrophages), as well as human fetal liver and the term
placenta. Negative controls were (1) sections incubated
with irrelevant antibodies and (2) sections incubated with
antibodies pre-absorbed with the IGF1 peptide (Abcam).
Sections were incubated overnight with the prediluted
antibody at 4°C and then with anti-rabbit micropolymer-
linked secondary antibody (ImmPress kit, Vector Labora-
tories) following the manufacturer’s instructions. Color
was developed using diaminobenzidine. IGF2 immunohis-
tochemistry was performed using a rabbit antibody from
Abcam (ab9574) that had previously been used to char-
acterize human tumor specimens [32], employing the ap-
proaches described for IGF1. Briefly, the sections were
incubated overnight with the IGF2 antibody (dilution of
1:100) at 4°C and then with anti-rabbit micropolymer-
linked secondary antibody (ImmPress kit) following the
manufacturer’s instructions.
IGF1R immunocytochemistry
The expression of IGF1R in mixed human CNS cell cul-
ture was determined by immunohistochemistry using
anti-IGF1R antibody from R&D systems (MAB391), as
previously described [33]. Mixed human CNS cell cultures
were fixed in 100% ice-cold methanol and were then
permeabilized with 0.1% Triton X-100 detergent in PBS.
Blocking for endogenous peroxidase and for nonspecific
binding was performed with 3% H2O2, followed by 5%
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normal goat serum (NGS) in PBS, each for 30 min. Cul-
tures were incubated with primary antibody (dilution
of 1:1000) overnight at 4°C and then with the mouse
micropolymer-linked secondary antibody (ImmPress kit)
following the manufacturer’s instructions. Color was de-
veloped using diaminobenzidine.
Microglial culture
Human CNS cell cultures were prepared from human
fetal abortuses (gestational ages from 16 to 20 weeks) as
previously described [34] with minor modifications. All
tissue collection was approved by the Albert Einstein Col-
lege of Medicine Institutional Review Board. Primary
mixed CNS cultures were prepared by enzymatic and
mechanical dissociation of the cerebral tissue followed by
filtration through nylon meshes of 230- μm and 130-μm
pore size. Single cell suspensions were plated at 1 to 10 ×
106 cells per ml in DMEM (Cellgro, now ThermoFisher
Scientific) supplemented with 10% FBS (Gemini Bio-
products, Woodland, CA), penicillin (100 U/ml), strepto-
mycin (100 μg/ml) and Fungizone (0.25 μg/ml) (complete
medium) for 2 weeks, and then microglial cells were col-
lected by aspiration of the culture medium. Monolayers
of microglia were prepared in 60-mm tissue culture dishes
at 1 × 106 cells per 5 ml medium (for Q-PCR) or in 96-
well tissue culture plates at 4 × 104 per 0.1 ml medium
(for ELISA). Four to eighteen hours later, cultures were
washed to remove nonadherent cells (neurons and astro-
cytes). Microglial cultures were highly pure, and consisted
of >98% CD68+ cells.
Culture stimulation
The culture medium was changed to low-serum medium
(DMEM plus 0.05% FBS) before cell stimulation to re-
duce potential effects from other growth factors. Lipo-
polysaccharide (LPS) and poly(I:C) were purchased from
Sigma-Aldrich (St. Louis, MO) and used at 100 ng/ml
and 10 μg/ml, respectively. Recombinant human cytokines
(IL-1β, IFNγ, IL-4, and IL-13) were purchased from
Peprotech (Rocky Hill, NJ) and were used at 10 ng/ml, un-
less otherwise stated. Microglia were also stimulated with
dibutyryl adenosine 30, 50-cyclic monophosphate (db cAMP,
Sigma-Aldrich) at 0.5 to 5 mM, or with recombinant
growth hormone (R&D Systems, catalog no. 1067-GH) at
1 to 100 ng/ml. Cells were stimulated and harvested as spe-
cified in individual experiments.
Q-PCR
Quantitative real-time reverse-transcription PCR (Q-PCR)
was performed as described [35,36], using porphobilinogen
deaminase (PBDA) as an internal control. Briefly, total
RNA was extracted with TRIzol and PCR performed using
a SYBR green PCR mix and the ABI Prism 7900HT system
(Applied Biosystems). All values were expressed as the
increase relative to the expression of PBDA. The median
value of the replicates for each sample was calculated and
expressed as the cycle threshold (CT; cycle number at
which each PCR reaches a predetermined fluorescence
threshold, set within the linear range of all reactions): ΔCT
was calculated as CT of endogenous control gene (PBDA)
minus CT of target gene in each sample. The relative
amount of target gene expression in each sample was then
calculated as 2ΔCT. Fold change was calculated by dividing
the value (2ΔCT) of test sample by the value (2ΔCT) of
control sample (control = 1). Primers for Q-PCR were
IGF1: forward TGGATGCTCTTCAGTTCGTG, backward
TGGTAGATGGGGGCTGATAC; IGF2: forward ACACC
CTCCAGTTCGTCTGT, backward GGGGTATCTTGGG
GAAGTTGT; IGF2R: forward GAAGGTGAAGGTCGG
AGT, backward GAAGATGGTGATGGGATTTC; TNFα:
forward GGCGTGGAGCTGAGAGATAAC backward, GG
TGTGGGTGAGGAGCACAT.
ELISA
The levels of IGF1 and IGF2 were determined using hu-
man IGF1 antibody DuoSet (catalog no. DY291, detec-
tion limit ~50 pg/ml) purchased from R&D Systems
(Minneapolis, MN) and IGF2 ELISA kit (catalog no.
RHF350CK, detection limit ~300 pg/ml) from Antigenix
America (Huntington Station, NY) respectively, follow-
ing the manufacturer’s instructions. Briefly, polystyrene
96-well plates (Nunc) were pre-coated overnight at room
temperature with specific capture Ab, then blocked with
1% BSA in buffer A (PBS plus 0.1% Tween 20) for 2 h at
room temperature. The plates were then incubated with
standard IGF dilutions or cell culture media for 2 h at
room temperature, washed with buffer A, and incubated
with the biotinylated detection Ab for 2 h at room
temperature. After the second wash, the plates were incu-
bated with HRP-streptavidin for 30 min at room tem-
perature and washed again. The signal was developed
after addition of 3,3',5,5'-tetramethylbenzidine-peroxidase
EIA kit (Bio-Rad) for 4 to 10 min and the reaction was
stopped by 1M H2SO4. A microplate reader (Dynex Tech-
nologies) was used to detect the signals at 450 nm with
correction at 530 nm.
Western blot
Western blot analysis was performed as previously de-
scribed [11,35] with minor modifications. Briefly, cell
cultures in 60 mm dishes were scraped into lysis buffer
(PBS plus protease inhibitors from Sigma) at various
time points. Thirty micrograms of protein was separated
by 4 to 20% TGX polyacrylamide gel electrophoresis and
then transferred to a polyvinylidene difluoride mem-
brane. The blots were blocked in PBS-0.1% Tween-20
containing 5% nonfat milk and then incubated with anti-
bodies at 4°C for 16 h. Primary antibodies were against
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rabbit polyclonal IGF2 from Abcam (ab9574), applied at
a dilution of 1:500. An antibody against β-actin (Sigma-
Aldrich, A2228) or vinculin (Santa Cruz, SC5573) was
used as the loading control. The secondary antibody was
either horseradish peroxidase-conjugated anti-mouse or
anti-rabbit IgG (Pierce Biotechnology, Rockford, IL) and
was used at 1:1,000 for 1 h at room temperature. Signals
were developed using enhanced chemiluminescence (Pierce
Biotechnology). Densitometric analysis was performed
using Scion NIH Image software (Scion, Frederick, MD).
Preparation of mixed CNS cell cultures and neurotoxicity
assay
Mixed neuronal and glial cultures were generated by
replating the initial CNS cell cultures once into 96-well
tissue culture plates, as previously described [34,37].
Cultures were kept as monolayers in DMEM with 10%
FBS and antibiotics and used at approximately 4 to 6 weeks
in vitro. Cultures were stimulated with IL-1/IFNγ at 10 ng/ml
in low-serum medium (DMEM + 0.05% FBS) for 72 h to
induce neurotoxicity with or without recombinant human
IGF1 (catalog no. 100–11) and IGF2 (catalog no. 100–12)
purchased from Peprotech (NJ, Rocky Hill) at 10 ng/ml.
Neurotoxicity assay was performed by vital dye exclusion
(trypan blue) and microtubule-associated protein 2
(MAP2) immunostain, as previously described [37-39].
Statistical analysis for tissue culture studies
Normalized data (fold change over control) from differ-
ent brain cases were compared using one sample t test.
For multiple comparisons, one-way analysis of variance
(ANOVA) with Dunnett’s multiple comparison tests was
performed. All statistics were performed using the
GraphPad Prism 5.0 software.
Results
IGF1 is expressed in microglia and macrophages in
human CNS
Results of IGF1 immunohistochemistry in human CNS
using the HIV+ and HIV− brains are summarized in
Figure 1 and in Table 1. In all of these brains, the main
IGF1 immunoreactivity in the brain parenchyma was
Figure 1 IGF1 is expressed in human brain. IGF1 immunohistochemistry was performed on paraffin-embedded post-mortem human brain
sections from HIV+ and HIV− individuals. IGF1 staining was found in microglial nodules and multinucleated giant cells as well as perivascular
inflammatory cells (perivascular lymphocytes and macrophages) in HIV encephalitis brains (A-C). Examples of diffuse parenchymal microglial cell
staining are shown in HIV encephalitis, HIV+ and HIV− brains (D-F). Additional IGF1+ cell types included occasional endothelial cells (E: v =
vessels) and astrocytes (in E). IGF1 staining was also noted in the meninges (G) in vascular smooth muscle cells (v = vessels), as well as in
ependymal cells (H) in some brains (note strong microglial staining in the subependymal area in H). Controls included incubation of sections
with the peptide pre-absorbed antibody, which abrogated IGF1 immunoreactivity (I).
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detected in myeloid cells (microglia and macrophages).
For example, microglial nodules and multinucleated
giant cells (MGCs) (from HIV-infected microglia and
macrophages), the hallmark lesions of HIVE, were posi-
tive for IGF1 (Figure 1A,B). In addition, perivascular
macrophages and inflammatory cells were also positive
(Figure 1C). Parenchymal ramified microglial cells were
IGF1 positive in all three conditions (HIVE, HIV+, and
HIV− brains) (Figure 1D-F). In addition, occasional endo-
thelial cells and vascular smooth muscle cells within the
brain (Figure 1E) and meninges (Figure 1G), as well as
ependymal cells (Figure 1H) and rare astrocytes (Figure 1E)
or neurons (not shown) were IGF1-positive. A semiquanti-
tative assessment of IGF1 immunoreactivity is presented
in Table 1. These results together suggest that cells of mye-
loid lineage (microglia and macrophages) are the predom-
inant IGF1-expressing cells in human CNS parenchyma,
but other cells (including meningeal and vessel-associated
cells) also contribute to the IGF1 production.
We also attempted to determine IGF2 expression in hu-
man CNS by immunohistochemistry. A rabbit polyclonal
antibody from Abcam (ab9574), which had previously been
used to characterize human tumor specimens [32], was uti-
lized in this study. Using the approach described for IGF1
immunohistochemistry, we examined the same control and
HIV+ brain sections. All brain sections showed diffuse
background-like staining combined with some nuclear
staining (data not shown). The nuclear staining was also
observed in cultured microglia (not shown). Attempts with
additional commercial IGF2 antibodies were equally unsuc-
cessful, indicating either that the antibodies are not suitable
for tissue immunohistochemistry or that there is no signifi-
cant IGF2 expression in human CNS (see Discussion).
Regulation of cultured human microglial IGF1 and IGF2
mRNA expression by inflammatory mediators (Q-PCR)
We next examined the expression of IGF1 and IGF2 in pri-
mary human microglial cultures. The expression of IGF2R,
which we previously reported to be an IFNγ-inducible
novel microglial protein [29], and the proinflammatory
cytokine TNFα were also examined simultaneously in the
same cultures. Microglia were stimulated with Th1 (IFNγ)
or Th2 (IL-4, IL-13) cytokines, the toll-like receptor (TLR)
ligands (LPS or poly(I:C)), or medium alone (DMEM +
0.05% FBS) for 6 h at indicated doses, then mRNA expres-
sion was determined by Q-PCR. The mRNA levels for
IGF1, IGF2, IGF2R, and TNFα were expressed relative to
those in unstimulated cultures (control = 1). Results pooled
from several microglial cultures derived from different
brain cases are shown in Figure 2. They indicate that IGF1
mRNA expression was slightly suppressed by IFNγ but
was more potently suppressed by LPS and poly(I:C)
(Figure 2A). The effects of IL-4 and IL-13 were variable,
with no significant effects across different cases. In con-
trast, IGF2 mRNA was significantly upregulated by LPS
(Figure 2B), while IFNγ, IL-4, IL-13, and poly(I:C) had no
significant effect. IGF2R mRNA was upregulated by IFNγ
only (Figure 2C), consistent with our previous results
obtained with Western blot [29]. TNFα mRNA was deter-
mined to control for the efficacy of cytokine and TLR
ligands, and this showed that LPS and poly(I:C) potently
induced TNFα mRNA, as expected. In addition, a small
but significant induction and reduction of TNFα mRNA
was also observed by IFNγ and IL-4/IL-13, respectively
(Figure 2D, see Discussion). These results together show
that the expression of IGF1, IGF2, IGF2R, and TNFα is
distinctly regulated in human microglia.
Table 1 IGF1 expression in human brain









HIV encephalitisd Case 23 + + + ± + ependyma
Case 1 + + − + + ependyma
Case 3 ± + − + + −
Case 20 + + + + + ependyma, neurons
Case 22 + + + + + −
Case 9 + + + ± + −
No encephalitise Case 11 (HIV+) + NAf NAf NAf + −
Case 12 (HIV+) + NAf NAf NAf + −
Case 21(HIV+) + NAf NAf + + astrocytes
Case 18 (HIV−) + NAf NAf NAf + neurons
aInflammatory cells were mononuclear cells (lymphocytes, monocytes and macrophages) present in the brain parenchyma or in perivascular spaces; bIGF1
immunoreactivity was regularly associated with vessels in both brain parenchyma and meninges. Staining was present in smooth muscle cells, as well as in some
endothelial cells. Some meningeal arachnoid cells and macrophages were also occasionally IGF1 positive; cOther parenchymal IGF1positive cells included
ependymal cells, occasional astrocytes or rarely even neurons; dHIV encephalitis sections had characteristic pathology on H&E consisting of MGCs, microglial
nodules, activated microglia and macrophages, and mononuclear inflammatory cell infiltration; eControl brain sections had no significant pathology on H&E;
fNA (not applicable, since no inflammatory cells were present).
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Regulation of human astrocyte IGF1 and IGF2 mRNA
expression by inflammatory mediators (Q-PCR)
We have also performed Q-PCR analysis of astrocyte
cultures for comparison with microglia. Since human as-
trocytes do not respond to LPS but respond maximally
to IL-1, we treated cultures with the Th1 cytokine (IFNγ)
with and without IL-1β, the Th2 cytokines (IL-4, IL-13),
and the TLR ligand poly(I:C). The mRNA levels for
IGF1, IGF2, and TNFα were determined and expressed
relative to those in unstimulated cultures. Results from
two different astrocyte cases are shown in Figure 3.
Astrocyte IGF1 mRNA levels were not significantly
changed by inflammatory mediators, while IGF2 mRNA
levels were highly upregulated by IL-1β (±IFNγ). TNFα
was also highly induced by IL-1β/IFNγ, as previously
reported. Both IL-1β and poly(I:C) had lesser effects,
while IL-4 and IL-13 had no effect. IGF1 was undetect-
able in astrocyte culture supernatants (not shown).
These results suggest that while astrocyte IGF1 expres-
sion might be insignificant, IGF2 might be upregulated
under inflammatory conditions (see Discussion).
Regulation of human microglial IGF1 protein expression
(ELISA)
We next performed ELISA for IGF1 production in human
microglia. Microglial cultures were treated with various
cell stimuli as shown for Q-PCR analysis, and the 24 h
cultures supernatants were subjected to ELISA assay
(R&D DuoSet, sensitivity ≈50 pg/ml). As shown in
Figure 4A, the amounts of IGF1 protein in microglial su-
pernatants were relatively low (~100 pg/ml range) and the
samples stimulated with proinflammatory mediators
showed even lower levels. Microglial IGF1 levels were
suppressed by IFNγ or LPS, but IL-4 had no effect. The
IFNγ effect was dose-dependent, with suppressive effects
shown only in high concentrations (100 ng/ml or above).
In addition to inflammatory mediators, we tested add-
itional compounds that have been shown to modulate
IGF1 expression in other cell types [40,41]. Of these, the
cAMP analog db cAMP (0.5 to 5 mM) increased micro-
glial IGF1 production (Figure 4B). However, growth hor-
mone (1 to 100 ng/ml), the primary inducer of hepatic
IGF1, had no effect (data not shown). These results
Figure 2 Assessment of human microglial IGF1 and IGF2 mRNA expression by Q-PCR. Microglia cultures were treated with IFNγ (10 ng/ml),
IL-13 (10 ng/ml), IL-4 (10 ng/ml), LPS (100 ng/ml), poly(I:C) (10 μg/ml), or medium alone for 6 h and Q-PCR was performed for IGF1, IGF2, IGF2R,
and TNFα. Fold changes over control (medium alone) were calculated in each case and values from multiple microglial cases were pooled and
statistical significance analyzed using one sample t test (GraphPad Prism 5) * P < 0.05, ** P < 0.01, *** P < 0.001. IGF1 mRNA was suppressed
by IFNγ, LPS, or poly(I:C) (A), IGF2 mRNA increased by LPS (B), IGF2R mRNA increased by IFNγ (C), and TNFα mRNA increased by IFNγ, LPS or poly
(I:C) (see broken y axis) and suppressed by IL-4 or IL-13 (D).
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together show that IGF1 expression is cell-specific and that
human microglial IGF1 production is suppressed by
proinflammatory mediators (IFNγ or LPS), is not signifi-
cantly modulated by IL-4, and is increased by cAMP (see
Discussion).
Regulation of microglial IGF2 protein expression
We next attempted to determine the IGF2 protein levels
in microglial cultures by ELISA. A commercially available
ELISA that is compatible with culture supernatants was
obtained from Antigenix America but this had a detection
limit of ~300 pg/ml. Other commercial IGF2 ELISAs
(Alpco Diagnostics or Diagnostic System Laboratories, for
example) were not intended for tissue culture fluid assays
and had a similar low sensitivity. Microglial culture IGF2
levels were not detectable using these assays (not shown),
perhaps because of the assays’ low sensitivity. Therefore, we
next determined microglial IGF2 expression using Western
blot analysis (Figure 5). Cell lysates were separated in a 4 to
20% TGX polyacrylamide gradient gel and the blot was
probed with a rabbit anti-IGF2 antibody (Abcam), as de-
scribed. Representative results with densitometric ratios are
shown in Figure 5. A single band of ≈7.5 kDa (consistent
with the molecular mass of IGF2) was detected in micro-
glial cultures stimulated with LPS but not with IL-4, IL-13,
IFNγ, or poly(I:C) (Figure 5A). Time course analyses
showed that IGF2 upregulation by LPS was transient at 24
h (Figure 5B). These results together demonstrate that
IGF2 expression in human microglia is upregulated by LPS.
Expression of IGF1 receptor (IGF1R) in mixed neuronal
glial cultures
Both IGF1 and IGF2 signal through the IGF1R, suggesting
that both IGFs could promote neuronal survival by
activating the downstream Akt pathway, but a direct dem-
onstration of IGF peptides’ neurotrophic effects is rare. We
thus examined whether IGF1 and IGF2 confer neuropro-
tection in our well-characterized cytokine-induced neu-
ronal death assay using primary human neuronal glial
cultures [34,37]. First, we examined IGF1R expression by
immunocytochemistry of mixed human fetal CNS cultures
using an antibody that detects the extracellular domain of
human IGF1R (R&D Systems). As shown in Figure 6,
IGF1R expression was found predominantly in neurons
(small process-bearing cells) and the immunoreactivity was
localized to the cell membrane. Glial cells did not appear to
have significant IGF1R immunoreactivity. Stimulation of
the mixed cultures with various inflammatory mediators
did not affect the amount of IGF1R immunoreactivity ap-
preciably (Figure 6).
IGF1 and IGF2 rescue human fetal neurons from cytokine-
induced death
We next investigated whether IGFs have the neuropro-
tective effects in our mixed human fetal CNS cultures,
following a published protocol [34,37]. Briefly, cultures
consisting primarily of neurons and astrocytes and a
minor population of microglia were stimulated with IL-
1β/IFNγ (10 ng/ml each) for 3 days to determine the
extent of neuronal death. We examined the role of IGFs
by treating the cultures with either IGF1 or IGF2 at
10 ng/ml for 2 h prior to cytokine stimulation. Three
days later, neuronal death was determined by vital dye
exclusion (Figure 7A) or MAP2 immunostain (Figure 7B
and C). The results show that IL-1β/IFNγ-induced neu-
ronal death was significantly reduced by addition of
recombinant IGF1 or IGF2. Higher concentrations of
Figure 3 Assessment of human astrocyte IGF1 and IGF2 mRNA expression by Q-PCR. Astrocyte cultures were treated with IL-1β (±IFNγ) IL-
13, IL-4, poly(I:C) or medium alone for 6 h and Q-PCR was performed for IGF1, IGF2, and TNFα. Fold changes over control were calculated in each
case and values from two astrocyte cases are shown (bar = mean value). No significant changes were noted in astrocyte IGF1 mRNA following
treatment with inflammatory stimuli (A) but IGF2 mRNA was potently induced by IL-1β (±IFNγ) (B). TNFα mRNA was induced maximally by
IL-1β/IFNγ and less by IL-1β or poly(I:C) but not by IL-13 or IL-4 (C).
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IGFs (100 ng/ml) or the combination of IGF1 and IGF2
did not confer further protection (data not shown).
Discussion
Our study demonstrates that microglia and macrophages
are the main expressors of IGF1 in human CNS paren-
chyma. In addition, a number of other cell types located in
the subarachnoid space, the cerebrospinal fluid (CSF) brain
barrier, and the blood brain barrier (such as meninges,
ependymal cells, endothelial cells, and vascular smooth
muscle cells) expressed IGF1 immunoreactivity. These re-
sults are consistent with the previous studies of developing
rodents and human brains, which showed that IGF1 mRNA
is predominantly expressed by CNS mesenchymal cells
(meninges, enclosed vessels, macrophages, choroid plexus,
and so on) [42-44]. Additional recent rodent studies of
experimental CNS conditions reported that microglia
(and astrocytes in some instances) express IGF1
[45-48]. Less information is available on IGF2, but there
are reports that show that microglia in developing and
injured CNS express IGF2 protein [49-51]. In addition,
intracranial mesenchymal cells serve as sources of IGF2
Figure 4 IGF1 protein production by microglia as assessed by
ELISA. Microglia in triplicate cultures were stimulated with IFNγ
(10, 100, and 1000 ng/ml), IL-4 (10 ng/ml), LPS (100 ng/ml), or
medium alone (control) for 24 h and culture supernatants were
analyzed for IGF1 protein content by ELISA (A). Microglial cultures
were also exposed to different doses of db cAMP (0 to 10 mM)
(B) as shown and culture supernatants were analyzed for IGF1 by
ELISA. Microglial culture IGF1 levels were low (at the lower detection
range of the ELISA) and they were further decreased by
proinflammatory stimulants. Mean ± SD, One-way ANOVA with
Dunnett’s multiple comparisons * P <0.05, ** P <0.01, *** P <0.001.
Figure 5 IGF2 protein expression in human microglia is
upregulated by LPS. Microglia cultures were stimulated with different
stimuli, as described for Q-PCR assay, and Western blot analysis was
performed for IGF2 protein in a 4 to 20% polyacrylamide gradient gel
using a commercial antibody. Densitometric ratios are shown. Induction
of IGF2 (≈7.5 kDa) by LPS is shown in microglial samples treated for
24 h (A,B). Results are representative of three independent experiments.
Figure 6 IGF1R expression in human fetal neurons. Mixed
neuronal glial cultures stimulated for 24 h with IFNγ (10 or 100 ng/ml),
IL-4 (10 ng/ml), or LPS (not shown) or not (Control) and
immunostained for IGF1R using a commercial antibody. IGF1R
immunoreactivity (brown) was selectively expressed in small process-
bearing cells in these cultures (neurons) without appreciable
differences in the expression levels among various culture conditions.
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expression, as for IGF1 [42-44]. Our attempts to delineate
IGF2 expression in human CNS have resulted in minimal
staining of brain parenchyma. There are several possibil-
ities for this, including extremely low levels of expression
and inadequate antibodies for tissue staining. Additional
possibilities include rapid capture and degradation of IGF2
by the receptor IGF2R, which we found to be significantly
upregulated in activated microglial cells in the CNS [29].
More importantly, we show that cultured human mi-
croglia are significant sources of IGF1 and IGF2. Mouse
bone marrow macrophages and microglia have been
reported to produce ng/ml levels of IGF1 [6,52,53]. Further-
more, murine macrophage and microglia IGF1 production
is upregulated by IL-4 or IL-13 [52], but downregulated by
IFNγ [6,53], suggesting that IGF1 production is a function
of M2 activation. Yet another study of rat microglia showed
that IGF1 (and IGF2) are induced by LPS [50]. In the
current study, we find that human fetal microglia produce
relatively low levels (~100 pg/ml) of IGF1 and that this level
is potently suppressed by LPS (and poly(I:C)), as well as by
very high concentrations of IFNγ. The expression profile of
TNFα mRNA in microglial culture (Figure 2D) suggests
that TNFα might mediate the IGF1-suppressive effects of
LPS, poly(I:C), and even IFNγ in these cultures, establishing
an interesting relationship between IGF1 and TNFα.
Indeed, there is evidence that proinflammatory stimuli
suppress neuronal growth factor production. We have re-
cently reported that LPS potently suppresses another
microglial-derived neuronal growth factor, progranulin
[11]. It has also been shown that BDNF is suppressed by
LPS in the rat CNS in vivo [54]. These results together es-
tablish a relationship between macrophage and microglia
Figure 7 IGF1 or IGF2 significantly protects neurons from cytokine-induced toxicity. Mixed human fetal neuronal glial cultures were
stimulated with IL-1/IFNγ for 3 days to induce neurotoxicity. A subset of cultures was pre-treated with either IGF1 or IGF2 at 10 ng/ml. Neuronal
death was evaluated using viral dye exclusion (A) or MAP2 immunostain (B,C) as previously described [37]. IGF1 or IGF2 reversed the neuronal
dead caused by IL-1/IFNγ Results are mean ± SD from triplicate cultures, and are representative of five independent experiments with similar
results. One-way ANOVA with Dunnett’s multiple comparison tests. *P < 0.05, ** P < 0.01, *** P < 0.001.
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activation phenotypes and IGF1 production, and further
suggest that neurotrophic growth factor production is
suppressed in a proinflammatory (M1) environment but is
encouraged in an M2 environment. In addition to macro-
phage cell types, proinflammatory cytokines have also
been shown to inhibit IGF1 expression in systemic cells.
For instance, IL-1 and TNFα suppress (growth hormone-
induced) IGF1 mRNA expression in hepatocytes [55,56].
Despite extensive study, the molecular mechanism
underlying regulation of IGF1 transcription is not well
understood. The 50 regulatory region of the IGF-1 gene
contains a cAMP response element (CRE) [57,58]. Hu-
man microglial IGF1 expression was increased by db
cAMP, suggesting that IGF1 expression in these cells is
also under the control of CRE. As many neurotransmit-
ters (norepinephrine, dopamine, and so on) activate the
cAMP/protein kinase A (PKA) pathway, these results
suggest that IGF1 expression can be facilitated in the
neural environment. Conversely, under chronic neurode-
generative conditions (such as Alzheimer’s disease and
Parkinson’s disease), growth factors levels can be depleted,
as a result of selective neurotransmitter deficiencies. The
effect of proinflammatory mediators on IGF1 expression
might in part be explained as a consequence of their
role in cAMP/CRE activation. Together, these results indi-
cate intriguing relationships between neural environment,
growth factor production, and neuroinflammation [59,60].
Regulation of IGF2 has been extensively studied in tu-
mors, with little information available on non-neoplastic
cells. IGF2 is an imprinted gene and has an important
role during mouse development [16,20,25,61]. Excess
IGF2 is produced during fetal stage and failure of re-
moval of excess IGF2 due to IGF2R deficiency results in
fatal organ overgrowth due to overstimulation of IGF1R.
Less is known about the post-developmental role of
IGF2, but in human beings, IGF2 production continues
after birth. IGF2, similar to IGF1, signals through IGF1R
with resulting cell survival, growth, and metabolic effects
mediated by the PI3K/Akt pathways. In our investiga-
tion, IGF2 expression was uniquely upregulated by LPS
(in contrast to IGF1) in human microglia, (and by IL-1β
in astrocytes in culture), suggesting that the two IGF
peptides are under different regulatory controls. Several
sequences identified in the human IGF2 promoter in-
clude Sp1, Egr-1-like, C/EBP, and AP-1 sites [61], some
of which are inducible by LPS. Future studies are neces-
sary to elucidate the molecular mechanisms underlying
differential microglial IGF peptide expression.
IGF1 is a well-known survival factor for many different
cell types, including neurons. There is evidence that de-
creased IGF1 levels are correlated with impaired cognitive
function and neurodegeneration in humans. For instance,
increased serum TNFα and decreased IGF1 levels were
reported in Alzheimer’s patients, with the two showing a
significant negative correlation [26]. In another study, CSF
(but not serum) levels of IGF1 were found to be dimin-
ished in individuals with motor neuron disease [62]. Stud-
ies that directly investigated the neurotrophic effects of
IGF1 are rare. IGF1, in combination with erythropoietin,
has been shown to mitigate HIV gp120-induced neurotox-
icity in mouse in both in vivo and in vitro models [63].
IGF1 was neuroprotective against TNFα-induced toxicity
or HIV-infected cell supernatants-induced toxicity in ro-
dent cell lines [64]. Recent studies have assessed the effi-
cacy of exogenous IGF1 in reducing the inflammatory
response of rat astrocytes [65]. In contrast to IGF1, little is
known about the physiological function of IGF2 in the
nervous system. In the mouse, IGF2 has recently been
proposed as a critical component in memory enhance-
ment and consolidation via promoting survival and mat-
uration of hippocampal neurons [66,67]. In this study,
using human cells, we show that IGF1R is predominantly
expressed by neurons, and that recombinant IGF1 or
IGF2 individually confer significant protection from
cytokine-induced neuronal death and provide sustenance
of MAP2 protein expression. These results together sup-
port the notion that IGF family peptides are significant
survival factors for human or rodent neurons and that
IGF1 and IGF2 might provide future therapeutic targets
for neurodegenerative diseases.
Conclusions
In this study, we investigated whether IGF1 and IGF2
are expressed in human microglia in vivo and in vitro,
and whether their expression is modulated by inflamma-
tory cytokines. We also investigated whether IGF1 or
IGF2 modulate neuronal survival. We demonstrated that
IGFs are expressed in microglia and that their expression
is modulated differently; for example, LPS potently sup-
pressed IGF1 but increased IGF2. Lastly, we found that
both IGF1 and IGF2 conferred strong protection against
cytokine-mediated neuronal death in human fetal neuronal
culture, supporting their potential future therapeutic appli-
cations in various human CNS conditions. Our results
suggest that neuronal growth factors (IGF1, progranulin)
are negative regulated by proinflammatory stimuli and that
the negative impact of inflammation on neural growth fac-
tor production might contribute to neurodegeneration.
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